Mesenchymal stem cells for recurrent miscarriage.
Ramos FS., Perez J., Ng GK., Veltmeyer JD., Koumjian MP., Lin F.
Narrative Review on Scar, Chronic Inflammation, Immune Modulation, published in J Transl Med (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- J Transl Med (2026)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42032691
- DOI
- 10.1186/s12967-026-08179-x
Abstract (original English)
BACKGROUND: Recurrent pregnancy loss (RPL), affecting 1–5% of couples, is frequently driven by immunological dysregulation, including excessive natural killer (NK) cell cytotoxicity, reduced regulatory T cell (Treg) function, Th1/Th17 dominance, and inflammatory cytokine imbalance at the maternal-fetal interface. These abnormalities disrupt immune tolerance to the semi-allogeneic fetus, leading to implantation failure or early miscarriage. Current interventions (e.g. low-dose aspirin/heparin for antiphospholipid syndrome, intravenous immunoglobulin, or corticosteroids) show variable efficacy and limitations, particularly in unexplained cases. Mesenchymal stem cells (MSCs), with proven immunomodulatory, anti-inflammatory, and tissue-repair properties, have gained regulatory approval for severe immune dysregulation conditions like steroid-refractory graft-versus-host disease (GVHD), which shares pathophysiological parallels with immune-mediated RPL, including NK hyperactivity and deficient Treg tolerance. MAIN BODY: MSCs from sources such as bone marrow, adipose tissue, or umbilical cord exert context-dependent effects, secreting anti-inflammatory factors (e.g. IL-10, TGF-β), suppressing pro-inflammatory cytokines, inhibiting cytotoxic NK activity, and promoting Treg expansion and function to restore immune homeostasis. Preclinical studies in abortion-prone mouse models (e.g. CBA
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewPubMed
Clinical Applications of Autologous Fat Grafting in Pathological Hand Conditions.
Systematic Review with a reported sample of 7 on Osteoarthritis, Scar, published in J Hand Surg Asian Pac Vol (2026) — summary generated from the PubMed abstract.
- 2026
- n = 7
J Hand Surg Asian Pac Vol - Level AMeta-analysisPubMed
Stem cell therapy in thin endometrium and Asherman's syndrome: a systematic review and meta-analysis.
Meta-analysis with a reported sample of 323 on Scar, published in Eur J Obstet Gynecol Reprod Biol (2026) — summary generated from the PubMed abstract.
- 2026
- n = 323
Eur J Obstet Gynecol Reprod Biol - Level AMeta-analysisEurope PMC
Therapeutic value of mesenchymal stem cell-derived extracellular vesicles in hypertrophic and keloid scars: a systematic review and meta-analysis
Meta-analysis on Chronic Wound, Scar, published in Front Cell Dev Biol (2026) — summary generated from the PubMed abstract.
- 2026
Front Cell Dev Biol - Level AMeta-analysisPubMed
Efficacy and safety of autologous cell-based therapies for atrophic acne scar treatment: an updated systematic review and meta-analysis with in-depth methodological and clinical insights.
Meta-analysis with a reported sample of 500 on Chronic Wound, Scar, published in Front Cell Dev Biol (2026) — summary generated from the PubMed abstract.
- 2026
- n = 500
Front Cell Dev Biol - Level ASystematic ReviewEurope PMC
Comparative Efficacy and Safety of Fractional CO<sub>2</sub> Laser and Gold Microneedling Radiofrequency for Atrophic Acne Scars: A Systematic Review
Systematic Review on Chronic Wound, Scar, published in Skin Res Technol (2026) — summary generated from the PubMed abstract.
- 2026
Skin Res Technol - Level AMeta-analysisPubMed
Role of exosome therapy in reconstructive surgery: a review.
Meta-analysis on Chronic Wound, Scar, Immune Modulation, published in Front Med (Lausanne) (2026) — summary generated from the PubMed abstract.
- 2026
Front Med (Lausanne)1 citations